Kymera Therapeutics (KYMR) Return on Capital Employed (2020 - 2026)

Kymera Therapeutics (KYMR) has 7 years of Return on Capital Employed data on file, last reported at 21.85% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 21.85%, up 944.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 21.85% (up 944.0% YoY), and the FY2025 annual result was 27.36%, up 954.0% from the prior year.
• Return on Capital Employed grew to 21.85% in Q1 2026 per KYMR's latest filing, from 26.09% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 21.85% in Q1 2026 and troughed at 36.68% in Q3 2023.
• A 5-year average of 29.23% and a median of 30.8% in 2022 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2022 and 2024: Return on Capital Employed sank 1411 bps in 2022, then soared 1350 bps in 2024.
• A 5-year view of Return on Capital Employed shows it stood at 29.35% in 2022, then decreased by 18 bps to 34.6% in 2023, then gained by 19 bps to 27.87% in 2024, then rose by 6 bps to 26.09% in 2025, then climbed by 16 bps to 21.85% in 2026.
• Business Quant data shows KYMR's Return on Capital Employed at 21.85% in Q1 2026, 26.09% in Q4 2025, and 31.8% in Q3 2025.